The RAB9A antibody is a critical research tool for studying the RAB9A protein, a member of the Rab GTPase family. RAB9A regulates vesicular trafficking, particularly the transport of mannose-6-phosphate receptors from late endosomes to the trans-Golgi network (TGN) . Its role in cancer progression, viral entry, and lysosomal biogenesis has made it a focal point for biomedical investigations. This review synthesizes data on RAB9A antibody applications, validation, and research findings from diverse sources.
KD/KO Validation: Proteintech’s 11420-1-AP antibody has been validated in knockdown/knockout (KD/KO) models .
Cross-reactivity: Species-specific reactivity includes human, mouse, rat, monkey, and hamster .
Molecular Weight: All antibodies target the 23 kDa RAB9A protein .
Optimal Dilutions:
Liver Cancer: RAB9A promotes proliferation, invasion, and survival via AKT/mTOR signaling . Antibodies (e.g., 11420-1-AP) confirmed downregulation of pro-apoptotic proteins (Bax, cleaved caspase-3) and upregulation of anti-apoptotic Bcl2 .
Melanoma: Knockdown reduces tumor growth and induces apoptosis .
HPV Infection: Rab9a antibodies demonstrated its requirement for viral trafficking from endosomes to Golgi .